Guidelines aimed at promoting the standardisation of sleep apnoea services within pharmacies in Australia have been launched at PSA15.
The Practice guidelines for the provision of sleep apnoea services within pharmacy provide assistance to pharmacists on professional issues and obligations relating to pharmacy sleep apnoea services.
The National President of PSA, Joe Demarte, says the guidelines are a result of PSA’s ongoing recognition of the importance of continuity of care within the healthcare environment.
“These guidelines also promote policies and protocols designed to ensure effective channels of communication and collaboration between healthcare providers to ensure best possible outcomes for the patient,” Demarte says.
“They have been developed in collaboration with the Australasian Sleep Association with whom we have a memorandum of understanding to support pharmacist education in sleep health and sleep science.
“This MOU established a framework for commitment and cooperation between the PSA and ASA to underpin this education which has led to these very comprehensive guidelines.”
Demarte says that moderate-to-severe sleep apnoea, if left untreated, can lead to health problems which could include hypertension, cardiovascular disease, strokes, diabetes, and depression.
“In addition, untreated sleep apnoea, in addition to being a health risk, is a safety risk for many people including long-distance drivers,” he says.
“Pharmacies are frequented by consumers due to easy access and convenience; and pharmacists and pharmacy staff who are educated and trained in this area are well placed to provide sleep apnoea.”